Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption
New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy
Increasing Patient Awareness and International Commercial Activities Create Additional Growth Opportunities
Highlights included:
-
Revenues of
compared with$6.0 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence of sales to a historically large customer.$6.9 million -
Gross profit increased to
from$3.3 million in the third quarter of 2025 and gross margin improved to$2.7 million 55% from39.1% in the prior-year period. - Shipped 26 systems, including eight carried over from the second quarter of 2026 due to financing approval timing, compared with 16 in the prior-year period. Excluding those eight systems, 18 systems were shipped during the quarter, compared with six shipments to customers other than the Company’s historically largest customer in the third quarter of 2025.
- Continued physician education initiatives and expanded customer relationships, including initial system purchases by two large private equity-backed dermatology groups.
- Launched TreatSkinCancer.com, a consumer education resource designed to increase awareness of skin cancer treatment options, complementing the Company’s ongoing physician education initiatives.
-
Advanced international market-development activities across
Asia-Pacific , includingAustralia ,New Zealand ,China andHong Kong . - Subsequent to quarter end, placed the Company’s 1,000th SRT system, marking an important commercial milestone.
Management Commentary
"Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability," said Joseph Sardano, Chairman and Chief Executive Officer. “With dedicated reimbursement codes now in effect, our conversations with physicians are increasingly focused on how to bring SRT into their practices.
“Our vision is to make SRT a more widely understood and accessible non-invasive treatment option for appropriate patients with non-melanoma skin cancer. We are expanding physician education and patient awareness, including through TreatSkinCancer.com, while pursuing opportunities internationally and developing additional revenue streams tied to system utilization, software and services. The recent sale of our 1,000th SRT system is a milestone I am particularly proud of.
“We have spent years advancing the technology and growing our installed base. Today, we have a reimbursement framework that we believe can support broader adoption and a more scalable business. Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business,” concluded Sardano.
Third Quarter 2026 Financial Results
Revenues were
Unit shipments increased year-over-year to 26 systems, including eight carried over from the second quarter of 2026, compared with 16 systems in the prior-year period.
Cost of sales was
Gross profit was
General and administrative expense was
Selling and marketing expense was
Research and development expense was
Other income of
Net loss was
Adjusted EBITDA was a negative
Cash, restricted cash and cash equivalents were
Conference Call and Webcast
Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business update and answer questions.
Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (
The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.
Use of Non-GAAP Financial Information
This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in
SENSUS HEALTHCARE, INC.
|
||||||||||||||||
For the Three Months Ended |
|
For the Nine Months Ended |
||||||||||||||
September 30, |
|
September 30, |
||||||||||||||
| (in thousands) |
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
|
| Net loss, as reported | $ | (1,493 |
) |
$ | (943 |
) |
$ | (12,868 |
) |
$ | (4,552 |
) |
||||
| Add: | ||||||||||||||||
| Depreciation | 81 |
|
98 |
|
263 |
|
283 |
|||||||||
| Stock compensation expense | 70 |
|
73 |
|
209 |
|
219 |
|||||||||
| Income tax (benefit) expense | - |
|
(1,466 |
) |
4,079 |
|
(2,079 |
) |
||||||||
| Interest income, net | (126 |
) |
(160 |
) |
(368 |
) |
(528 |
) |
||||||||
| Adjusted EBITDA, non-GAAP | $ | (1,468 |
) |
$ | (2,398 |
) |
$ | (8,685 |
) |
$ | (6,657 |
) |
||||
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or “potential,” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this release as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable. Any forward-looking statements that we make in this release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this release is filed, except as may be required by applicable law.
SENSUS HEALTHCARE, INC.
|
||||||||||||||||
For the Three Months Ended |
|
For the Nine Months Ended |
||||||||||||||
September 30, |
|
September 30, |
||||||||||||||
| (in thousands, except shares and per share data) |
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
||||||||||
| Revenues | $ |
5,995 |
|
$ |
6,884 |
|
$ |
11,679 |
|
$ |
22,543 |
|
||||
| Cost of sales |
|
2,707 |
|
|
4,171 |
|
|
6,632 |
|
|
12,573 |
|
||||
| Gross profit |
|
3,288 |
|
|
2,713 |
|
|
5,047 |
|
|
9,970 |
|
||||
| Operating expenses: | ||||||||||||||||
| General and administrative |
|
2,253 |
|
|
1,917 |
|
|
6,079 |
|
|
6,111 |
|
||||
| Selling and marketing |
|
1,548 |
|
|
1,546 |
|
|
4,319 |
|
|
5,122 |
|
||||
| Research and development |
|
1,106 |
|
|
1,819 |
|
|
3,806 |
|
|
5,896 |
|
||||
| Total operating expenses |
|
4,907 |
|
|
5,282 |
|
|
14,204 |
|
|
17,129 |
|
||||
| Loss from operations |
|
(1,619 |
) |
|
(2,569 |
) |
|
(9,157 |
) |
|
(7,159 |
) |
||||
| Other income: | ||||||||||||||||
| Interest income, net |
|
126 |
|
|
160 |
|
|
368 |
|
|
528 |
|
||||
| Other income, net |
|
126 |
|
|
160 |
|
|
368 |
|
|
528 |
|
||||
| Loss before income tax |
|
(1,493 |
) |
|
(2,409 |
) |
|
(8,789 |
) |
|
(6,631 |
) |
||||
| Provision for (benefit from) income taxes |
|
- |
|
|
(1,466 |
) |
|
4,079 |
|
|
(2,079 |
) |
||||
| Net loss | $ |
(1,493 |
) |
$ |
(943 |
) |
$ |
(12,868 |
) |
$ |
(4,552 |
) |
||||
| Net loss per share – basic | $ |
(0.09 |
) |
$ |
(0.06 |
) |
$ |
(0.78 |
) |
$ |
(0.28 |
) |
||||
| diluted | $ |
(0.09 |
) |
$ |
(0.06 |
) |
$ |
(0.78 |
) |
$ |
(0.28 |
) |
||||
| Weighted average number of shares used in computing net loss per share – basic |
|
16,462,059 |
|
|
16,320,036 |
|
|
16,462,255 |
|
|
16,327,233 |
|
||||
| diluted |
|
16,462,059 |
|
|
16,320,036 |
|
|
16,462,255 |
|
|
16,327,233 |
|
||||
SENSUS HEALTHCARE, INC.
|
||||||||
As of September 30, |
|
As of December 31, |
||||||
| (in thousands, except shares and per share data) | 2026 |
|
2025 |
|||||
(unaudited) |
|
|
|
|||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash, restricted cash, and cash equivalents | $ | 12,920 |
|
$ | 22,083 |
|
||
| Accounts receivable, net | 1,403 |
|
6,041 |
|
||||
| Inventories | 17,965 |
|
14,563 |
|
||||
| Prepaid inventory | - |
|
1,522 |
|
||||
| Notes receivable, current portion | 609 |
|
- |
|
||||
| Other current assets | 1,687 |
|
1683 |
|
||||
| Total current assets | 34,584 |
|
45,892 |
|
||||
| Property and equipment, net | 2,662 |
|
1,976 |
|
||||
| Deferred tax asset | - |
|
4,079 |
|
||||
| Operating lease right-of-use assets, net | 265 |
|
452 |
|
||||
| Notes receivable, net of current portion | 2,731 |
|
352 |
|
||||
| Other noncurrent assets | 309 |
|
288 |
|
||||
| Total assets | $ | 40,551 |
|
$ | 53,039 |
|
||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 3,746 |
|
$ | 3,343 |
|
||
| Product warranties | 302 |
|
275 |
|
||||
| Operating lease liabilities, current portion | 278 |
|
262 |
|
||||
| Deferred revenue, current portion | 785 |
|
842 |
|
||||
| Total current liabilities | 5,111 |
|
4,722 |
|
||||
| Operating lease liabilities, net of current portion | - |
|
209 |
|
||||
| Deferred revenue, net of current portion | - |
|
10 |
|
||||
| Total liabilities | 5,111 |
|
4,941 |
|
||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | - |
|
- |
|
||||
| Common stock, |
169 |
|
169 |
|
||||
| Additional paid-in capital | 46,300 |
|
46,090 |
|
||||
| Treasury stock, 593,036 shares at cost, at September 30, 2026 and December 31, 2025 | (3,876 |
) |
(3,876 |
) |
||||
| (Accumulated deficit) retained earnings | (7,153 |
) |
5,715 |
|
||||
| Total stockholders’ equity | 35,440 |
|
48,098 |
|
||||
| Total liabilities and stockholders’ equity | $ | 40,551 |
|
$ | 53,039 |
|
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20261112617659/en/
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Source: Sensus Healthcare, Inc.